Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: A randomized, double blind, placebo-controlled human laboratory study

Drug and Alcohol Dependence

Volumn 141, Issue , 2014, Pages 72-78

  Verrico, Christopher D ^a   Haile, Colin N ^a   Mahoney, James J ^a   Thompson Lake, Daisy G Y ^a   Newton, Thomas F ^a   Ii, Richard De La Garza ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cocaine; Escitalopram; Modafinil; Subjective effects

Indexed keywords

COCAINE; ESCITALOPRAM; MODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; CITALOPRAM; DOPAMINE UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COCAINE DEPENDENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; REWARD; AFFECT; BLOOD PRESSURE; DECISION MAKING; DRUG EFFECTS; DRUG INTERACTION; HEART RATE; MIDDLE AGED;

ADULT; AFFECT; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CHOICE BEHAVIOR; CITALOPRAM; COCAINE; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 84903174970     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.05.008     Document Type: Article

References (61)

1. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., Smith E.V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., Somoza E., Urschel H.C., Elkashef A.M. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104:133-139.
2. Andersen M.L., Kessler E., Murnane K.S., McClung J.C., Tufik S., Howell L.L. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology 2010, 210:439-448.
3. Cone E.J. Pharmacokinetics and pharmacodynamics of cocaine. J. Anal. Toxicol. 1995, 19:459-478.
4. Czoty P.W., Ginsburg B.C., Howell L.L. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 2002, 300:831-837.
5. De La Garza R., Zorick T., London E.D., Newton T.F. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend. 2010, 106:173-180.
6. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003, 70:29-37.
7. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
8. Dackis C.A., Kampman K.M., Lynch K.G., Plebani J.G., Pettinati H.M., Sparkman T., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J. Subst. Abuse Treat. 2012, 43:303-312.
9. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci. Lett. 1998, 253:135-138.
10. Filip M., Alenina N., Bader M., Przegalinski E. Behavioral evidence for the significance of serotoninergic (5-HT) receptors in cocaine addiction. Addict. Biol. 2010, 15:227-249.
11. Grabowski J., Rhoades H., Elk R., Schmitz J., Davis C., Creson D., Kirby K. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J. Clin. Psychopharmacol. 1995, 15:163-174.
12. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 2001, 21:522-526.
13. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 2004, 29:1439-1464.
14. Groman S.M., Jentsch J.D. Cognitive control and the dopamine D(2)-like receptor: a dimensional understanding of addiction. Depress. Anxiety 2012, 29:295-306.
15. Haile C.N., Mahoney J.J., Newton T.F., De La Garza R. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol. Ther. 2012, 134:260-277.
16. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
17. Heal D.J., Buckley N.W., Gosden J., Slater N., France C.P., Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil. Neuropharmacology 2013, 73:348-358.
18. Hotsenpiller G., Giorgetti M., Wolf M.E. Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure. Eur. J. Neurosci. 2001, 14:1843-1855.
19. Howell L.L. Nonhuman primate neuroimaging and cocaine medication development. Exp. Clin. Psychopharmacol. 2008, 16:446-457.
20. Howell L.L., Carroll F.I., Votaw J.R., Goodman M.M., Kimmel H.L. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 320:757-765.
21. Kalechstein A.D., Mahoney J.J., Yoon J.H., Bennett R., De la Garza R. Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology 2013, 64:472-478.
22. Kalivas P.W., Duffy P. Repeated cocaine administration alters extracellular glutamate in the ventral tegmental area. J. Neurochem. 1998, 70:1497-1502.
23. Keys A.S., Mark G.P., Emre N., Meshul C.K. Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Synapse 1998, 30:393-401.
24. Kim W., Tateno A., Arakawa R., Sakayori T., Ikeda Y., Suzuki H., Okubo Y. In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I. Int. J. Neuropsychopharmacol. 2014, 17:697-703.
25. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., Fischman A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 2006, 319:561-569.
26. Mahler S.V., Hensley-Simon M., Tahsili-Fahadan P., Lalumiere R.T., Thomas C., Fallon R.V., Kalivas P.W., Aston-Jones G. Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. Addict. Biol. 2012, 19:49-60.
27. Malcolm R., Swayngim K., Donovan J.L., Devane C.L., Elkashef A., Chiang N. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse 2006, 32:577-587.
28. Martinez D., Carpenter K.M., Liu F., Slifstein M., Broft A., Friedman A.C., Kumar D., Van Heertum R., Kleber H.D., Nunes E. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am. J. Psychiatry 2011, 168:634-641.
29. Moeller F.G., Schmitz J.M., Steinberg J.L., Green C.M., Reist C., Lai L.Y., Swann A.C., Grabowski J. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am. J. Drug Alcohol Abuse 2007, 33:367-378.
30. Mooney M.E., Herin D.V., Schmitz J.M., Moukaddam N., Green C.E., Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009, 101:34-41.
31. Newton T.F., De La Garza R., Brown G., Kosten T.R., Mahoney J.J., Haile C.N. Noradrenergic α1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. PLoS One 2012, 7:e30854.
32. Nord M., Finnema S.J., Halldin C., Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int. J. Neuropsychopharmacol. 2013, 16:1-10.
33. Oliveto A., Poling J., Mancino M.J., Williams D.K., Thostenson J., Pruzinsky R., Gonsai K., Sofuoglu M., Gonzalez G., Tripathi S., Kosten T.R. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction 2012, 107:131-141.
34. Pani P.P., Trogu E., Vecchi S., Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst. Rev. 2011, 12:CD002950.
35. Pierce R.C., Bell K., Duffy P., Kalivas P.W. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J. Neurosci. 1996, 16:1550-1560.
36. Reichel C.M., See R.E. Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. Psychopharmacology 2010, 210:337-346.
37. Reid M.S., Berger S.P. Evidence for sensitization of cocaine-induced nucleus accumbens glutamate release. NeuroReport 1996, 7:1325-1329.
38. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
39. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. Trends Pharmacol. Sci. 2006, 27:612-618.
40. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J. 2007, 9:E1-E10.
41. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp. Clin. Psychopharmacol. 2008, 16:458-474.
42. Rowley H.L., Kulkarni R., Gosden J., Brammer R., Hackett D., Heal D.J. Lisdexamfetamine and immediate release d-amfetamine-differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology 2012, 63:1064-1074.
43. Schmaal L., Veltman D.J., Nederveen A., van den Brink W., Goudriaan A.E. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropharmacology 2012, 37:2143-2152.
44. Schmitt K.C., Reith M.E. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 2011, 6:e25790.
45. Schmitz J.M., Averill P., Stotts A.L., Moeller F.G., Rhoades H.M., Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 2001, 63:207-214.
46. Schmitz J.M., Rathnayaka N., Green C.E., Moeller F.G., Dougherty A.E., Grabowski J. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front. Psychiatry 2012, 3:77.
47. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010, 105:38-48.
48. Spealman R.D. Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology 1993, 112:93-99.
49. Substance Abuse and Mental Health Services Administration Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD, HHS Publication No (SMA) 13-4795.
50. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
51. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS), 2001-2011. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-65 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD, HHS Publication No (SMA) 13-4772.
52. Thomas M.J., Beurrier C., Bonci A., Malenka R.C. Long-term depression in the nucleus accumbens: a neural correlate of behavioral sensitization to cocaine. Nat. Neurosci. 2001, 4:1217-1223.
53. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003, 165:260-269.
54. United Nations Office on Drugs and Crime (UNODC) World Drug Report 2010, United Nations Publication, Sales No. E.10.XI.13.
55. Verrico C.D., Haile C.N., Newton T.F., Kosten T.R., De La Garza R. Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opin. Invest. Drugs 2013, 22:1549-1568.
56. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301:1148-1154.
57. Volkow N.D., Fowler J.S., Wang G.J., Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol. Learn. Mem. 2002, 78:610-624.
58. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Vitkun S., Logan J., Gatley S.J., Pappas N., Hitzemann R., Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386:827-830.
59. Walsh S.L., Cunningham K.A. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology 1997, 130:41-58.
60. Walsh S.L., Preston K.L., Sullivan J.T., Fromme R., Bigelow G.E. Fluoxetine alters the effects of intravenous cocaine in humans. J. Clin. Psychopharmacol. 1994, 14:396-407.
61. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., Prisinzano T.E., Baumann M.H. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther. 2009, 329:738-746.